Clinical Scorecard: Prognostic Significance of 18F-FDG Uptake Ratios Between Brain/Cerebellum and Liver

At a Glance

Key Highlights

• Brain/liver or cerebellum/liver 18F-FDG uptake ratios correlate with prognosis, with lower ratios (<2.5) associated with inferior survival.
• Cerebellum/liver index for prognosis (CLIP) is preferred due to consistent cerebellar inclusion in PET/CT and less metabolic variability.
• Continuous modeling of uptake ratios may provide better prognostic information than dichotomous cut-offs.

Guideline-Based Recommendations

Diagnosis

• Use 18F-FDG PET/CT to measure cerebellum or brain SUVmax and mean liver uptake to calculate uptake ratios.
• Prefer cerebellum/liver ratio (CLIP) for reproducibility and reduced confounding from neurodegenerative changes.

Management

• Consider uptake ratio values as prognostic indicators to stratify patients for risk and guide therapeutic decisions.
• Incorporate uptake ratios alongside established prognostic indexes for comprehensive assessment.

Monitoring & Follow-up

• Monitor changes in uptake ratios over time to assess disease progression or response to therapy.
• Account for potential confounders such as patient age and glycemia when interpreting uptake values.

Risks

• Be aware of limitations including variability in PET/CT field of view, metabolic changes due to neurodegeneration, and glycemic status.
• Avoid over-reliance on dichotomous cut-offs due to risk of misclassification and loss of prognostic information.

Patient & Prescribing Data

Patients with lymphoid malignancies undergoing PET/CT imaging prior to therapy

Lower cerebellum/liver or brain/liver 18F-FDG uptake ratios identify patients with higher risk of progression and inferior survival, potentially guiding intensity of treatment.

Clinical Best Practices

• Use SUVmax of the cerebellum rather than average uptake to enhance measurement reproducibility.
• Normalize cerebellar or brain uptake to mean liver uptake to account for systemic metabolic variations.
• Consider continuous variable modeling of uptake ratios rather than fixed cut-offs for prognostic evaluation.
• Account for patient-specific factors such as age and glycemia when interpreting PET/CT uptake ratios.

References

• Dingli et al. study on brain/liver 18F-FDG uptake ratio in multiple myeloma
• Hanaoka et al. 2010 study on tumor mass competing with brain glucose uptake in non-Hodgkin lymphomas
• Introduction of CLIP as prognostic factor in lymphomas (2021)
• CLIP studies in follicular lymphomas and diffuse large B-cell lymphomas
• CLIP in Post-Transplant Lymphoproliferative Disorders
• Study on total metabolic tumor volume and uptake in Hodgkin’s lymphoma
• Murairi et al. study on continuous modeling of CLIP in diffuse large B-cell lymphoma